NASDAQ-SMALL:TTNP

Titan Pharmaceuticals Announces Board Expansion and Management Changes

Retrieved on: 
Tuesday, August 16, 2022

Mr. Lazar succeeds Marc Rubin, M.D., who will no longer serve as Executive Chairman, but will remain on the Board.

Key Points: 
  • Mr. Lazar succeeds Marc Rubin, M.D., who will no longer serve as Executive Chairman, but will remain on the Board.
  • Mr. Ben-Tzvi is a member of the Israel Bar Association, and is also licensed as a Notary by the Israeli Ministry of Justice.
  • As a trader and portfolio manager at hedge funds, his areas of expertise included the development of trading strategies, portfolio management and deal structuring.
  • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura long-term, continuous drug delivery technology.

Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant

Retrieved on: 
Tuesday, July 5, 2022
FDA, Opioid use disorder, Addiction medicine, Securities Act of 1933, Securities Exchange Act of 1934, National Institute, Investigational New Drug, Marketing, Titan Pharmaceuticals, OUD, SAN, Food, IND, Drug Quality and Security Act, CA, Medication, NIDA, NASDAQ, Patent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Titan, Proneura prolongata

Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan, commented, "FDA clearance of the IND for our ProNeura-based nalmefene implant marks an important milestone in developing a novel product that may help answer the call for long-term treatment options in addiction medicine.

Key Points: 
  • Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan, commented, "FDA clearance of the IND for our ProNeura-based nalmefene implant marks an important milestone in developing a novel product that may help answer the call for long-term treatment options in addiction medicine.
  • We are very grateful for the support we received from the National Institute for Drug Addiction, or NIDA, that enabled us to meet this objective."
  • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeuralong-term, continuous drug delivery technology.
  • In December 2021, Titan commenced a process to explore and evaluate strategic alternatives to enhance shareholder value.